23andMe, a consumer genetics and research company, went public via a merger with VG Acquisition, a SPAC sponsored by Virgin Group, in a $3.5bn deal. "As a fellow industry disruptor as well as early investor in 23andMe, we are thrilled to partner with Sir Richard Branson and VG Acquisition as we approach the next phase of our business, which will create new opportunities to revolutionize personalized healthcare and medicine. We have always believed that healthcare needs to be driven by the consumer, and we have a huge opportunity to help personalize the entire experience at scale, allowing individuals to be more proactive about their health and wellness. Through a genetics-based approach, we fundamentally believe we can transform the continuum of healthcare," Anne Wojcicki, 23andMe CEO and Co-Founder.